Skip to content Skip to footer
Big news

mbiomics raises EUR 13 million in first closing of Series A round

“We are thrilled to have the support of such a strong group of investors who share our vision of using the power of the gut microbiome to develop targeted therapies. This funding will enable us to build our platform, accelerate the identification of our first lead drug candidates, and speed up the research efforts towards clinical validation.”

Dr. Laura Figulla
co-founder and CEO of mbiomics

Learn what our investors think about mbiomics

mbiomics GmbH

Kistlerhofstr. 70
Building 79
81379 Munich, Germany

+49 89 7199 8662

Get In Touch

mbiomics © 2023. All Rights Reserved.